secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001737287-23-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q1 net loss $98.7M, cash $514M; clinical progress in ALLO-501A and ALLO-316
--------------------------------------------------------------------------------

- Net loss $98.7M ($0.68/share); R&D $80.2M, G&A $18.9M; cash $514M as of March 31, 2023.
- Phase 2 ALPHA2 trial enrollment ongoing for ALLO-501A in R/R large B cell lymphoma; expects enrollment completion 1H 2024.
- Initiated EXPAND trial to support licensure of ALLO-647; randomized ~70 patients to FCA90 vs FC alone before ALLO-501A.
- Interim Phase 1 data on ALLO-316 in RCC: 3 of 10 CD70+ patients achieved partial response; disease control rate 100% in CD70+ subset.
- Appointed Timothy Moore as Chief Technical Officer; fiscal 2023 guidance: cash burn ~$230M, GAAP OpEx ~$340M, runway into Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/0001737287-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728723000051/allo-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001737287-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer